Supplements and Compounds Library

Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.

All Library Articles Presentations Spotlights News

Showing 25–48 of 175

Wiley Aging CellMay 3, 2026

Vitamin K2 Extends Lifespan by Alleviating Mitochondrial Stress via the JNK‐1/SIR‐2.1/DAF‐16 Signaling Axis in Caenorhabditis elegans

Vitamin K2 at optimal concentrations (5 μM) extends lifespan in C. elegans by activating a signaling pathway that protects mitochondria from oxidative stress, maintains ATP production, and enhances cellular stress resistance. This mechanism operates through preservation of mitochondrial function and reduction of reactive oxygen species accumulation.

Peter Attia MDFeb 21, 2026

GLP-1 drugs fail to slow cognitive decline in Alzheimer’s disease

Recent evidence indicates GLP-1 receptor agonists do not slow cognitive decline in established Alzheimer's disease, despite theoretical mechanistic rationale and their known metabolic benefits. This finding redirects focus toward earlier intervention windows and prevention strategies rather than disease reversal in advanced stages.

Longevity.TechnologyMar 11, 2026

GLP-1 drugs hint at protection against neurodegeneration

GLP-1 receptor agonists show mechanistic promise against neurodegeneration through multiple pathways—improved mitochondrial function, enhanced cellular cleanup, and reduced inflammation—but human evidence remains preliminary, with mixed cognitive outcomes in early trials and inconsistent results across disease types.

Longevity.TechnologyFeb 17, 2026

As obesity drugs go oral and access grows, so do fakes

The transition from injectable GLP-1 drugs to oral formulations is expanding patient access and treatment options, but creates new vulnerabilities to counterfeit products that pose direct safety risks. Regulatory vigilance and supply chain authentication will be critical as the weight-loss drug market scales to an estimated $100 billion by 2030.

Nature AgingMar 3, 2026

Advancing senescence translation through the Senotherapeutics Biomarker Consortium

The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.

Wiley Aging CellMar 31, 2026

Targeting Mitochondrial Stress Responses: Terbinafine and Miglustat as Novel Lifespan and Healthspan Modulators

Terbinafine and miglustat, FDA-approved drugs, extend lifespan and healthspan by inducing mitochondrial stress responses through coordinated activation of ATFS-1 and DAF-16 pathways. This mechanism represents a distinct integration of mitochondrial and insulin signaling stress responses relevant to aging intervention.

Longevity.TechnologyFeb 5, 2026

Weight returns fast after quitting GLP-1 drugs, study and experts say

Weight loss achieved through GLP-1 medications returns rapidly after discontinuation—approximately one pound per month, with most patients regaining initial weight within two years. This rebound occurs nearly four times faster than weight regain following diet or exercise cessation, underscoring that pharmacological intervention without sustained lifestyle modification produces temporary rather than durable health outcomes.

Longevity.TechnologyApr 7, 2026

Allergan Aesthetics finds its next growth engine in GLP-1s

GLP-1 weight-loss medications are creating a new patient population in aesthetic medicine, with 52% of GLP-1-treated patients expressing concerns about facial appearance changes and 32% being new to aesthetic practices. This represents market expansion rather than simple demand shifting, driven by patients seeking natural-looking, lower-commitment interventions to address facial volume loss during weight loss.

Wiley Aging CellFeb 26, 2026

DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment

Senolytic treatments did not reverse epigenetic signatures associated with cellular senescence, despite reducing senescent cell burden. This finding questions whether DNA methylation changes adequately capture senescence biology and whether current aging biomarkers respond as expected to geroscience interventions.

LifeSpan.ioApr 28, 2026

A Popular Senolytic Treatment Causes Brain Damage in Mice

Dasatinib and quercetin (D+Q), a widely used senolytic combination, impairs oligodendrocyte function and reduces myelination in the brain through endoplasmic reticulum stress, causing morphological changes similar to those seen in multiple sclerosis. This finding indicates that senolytic interventions carry neurological risks that warrant careful evaluation before clinical deployment.

Wiley Aging CellApr 9, 2026

Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza

Senolytic treatment with ABT-263 reduced lung and intestinal inflammation and prevented long-term pulmonary damage in aged mice infected with influenza, though it did not reduce viral replication itself. The findings indicate that pre-existing senescent cells drive inflammatory pathology rather than viral control, suggesting a therapeutic target for improving outcomes in older adults.

Longevity.TechnologyMar 23, 2026

Gubra-AbbVie obesity drug nears 10% weight loss

ABBV-295, an amylin-mimetic therapy from Gubra and AbbVie, produced 7.75–9.79% weight loss over 12 weeks in Phase 1 trials with a favorable safety profile. The drug targets a distinct hormonal pathway from current GLP-1 therapies, offering potential for multi-signal appetite regulation and sustained metabolic improvement.

Longevity.TechnologyMar 18, 2026

Three drugs in major study to prove their capacity to slow aging

UT Health San Antonio is launching VITAL-H, a $38 million clinical trial enrolling over 700 adults to test whether three existing drugs—rapamycin, semaglutide, and dapagliflozin—can slow biological aging in humans. This represents the first large-scale human trial specifically designed to evaluate pharmaceutical intervention in aging processes.

Longevity.TechnologyFeb 26, 2026

$30.8m funds Cambrian Bio’s bid to preserve resilience in aging

Cambrian Bio received $30.8 million in ARPA-H funding to test whether a selective mTORC1 inhibitor can preserve intrinsic capacity—the physical and metabolic resilience that maintains function during aging—before disease manifests. This represents a fundamental shift from treating established disease to intervening in the aging process itself, with success measured through a composite biomarker framework rather than disease endpoints.

Longevity.TechnologyApr 17, 2026

Rubedo: the senolytic alchemist of aging biology

Rubedo Life Sciences has advanced RLS-1496, a first-in-class GPX4 modulator senolytic, through Phase 1 human trials based on the company's ALEMBIC AI platform for identifying senescent cell vulnerabilities. This represents a shift from repurposed compounds toward precision-targeted senolytics designed to eliminate dysfunctional cells while sparing healthy tissue.

Wiley Aging CellMay 8, 2026

Targeting Hyperoxia‐Induced Cellular Senescence in Developing Human Airway Cells: Senomorphics Versus Senolytics Versus Antioxidants

Moderate hyperoxia induces cellular senescence in developing airway tissue, with lasting consequences for lung function. Three mechanistically distinct interventions—Fucoidan, Dasatinib plus Quercetin, and MitoQ—each mitigate senescence through different pathways, offering potential strategies to prevent hyperoxia-related lung disease in premature infants.

Nature - npj AgingFeb 10, 2026

Frailty phenotype reveals heterogeneity in aging and distinct taurine associations

Aging presents distinct phenotypic pathways with different metabolic signatures, particularly involving taurine metabolism. Identifying these heterogeneous frailty patterns enables targeted intervention strategies rather than one-size-fits-all approaches to age-related decline.

Longevity.TechnologyApr 17, 2026

New longevity drug SRN-901 shows 33% lifespan boost

SRN-901, a five-component oral combination therapy, demonstrated a 33% increase in median lifespan and 70% reduction in frailty progression in mice, with preserved physical function and reduced tumor incidence. The multi-pathway approach contrasts with single-target interventions, suggesting that aging requires simultaneous modulation of interconnected biological processes rather than isolated molecular manipulation.

LT WireApr 17, 2026

GNC adds MitoQ Pure and MitoQ NAD to The Drop

GNC has introduced MitoQ Pure and MitoQ NAD+ Dual Action supplements targeting mitochondrial function and oxidative stress reduction. Both formulations address energy production and cellular aging through distinct mechanisms—direct antioxidant support and NAD+ level optimization.

LT WireApr 20, 2026

Seragon study shows SRN-901 extends median lifespan in mice

SRN-901, an oral combinatorial drug, extended median remaining lifespan by 33% in aged mice on a Western diet, with a 46% reduction in hazard of death and 70% attenuation of frailty progression. Multi-omics analysis indicated upregulation of DNA repair and metabolic pathways alongside suppression of inflammatory and oxidative stress responses.

Longevity.TechnologyApr 23, 2026

Omada Health study boosts quality of GLP-1 weight loss

A 12-week study of GLP-1 users receiving structured digital support achieved 1.8 times greater total weight loss, with twice the fat loss and nearly threefold greater muscle preservation compared to medication alone. The research demonstrates that weight loss quality—measured by body composition and functional outcomes—is a more meaningful indicator of health benefit than weight reduction alone.

Longevity.TechnologyApr 9, 2026

NADMED backs Cleveland Clinic transplant study

Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.

Longevity.TechnologyMar 10, 2026

Novo’s triple-G obesity drug hits 19.7% loss in China trial

A triple-agonist obesity drug (UBT251) achieved 19.7% weight loss over 24 weeks in a Phase 2 trial, with concurrent improvements in glucose, blood pressure, and lipid profiles. This represents a shift toward multi-system metabolic intervention rather than single-pathway hormone modulation, with implications for reducing chronic disease burden across the lifespan.

Wiley Aging CellMar 16, 2026

Magnesium Deficiency Accelerates Gut Aging and Increases Susceptibility to Colitis

Magnesium deficiency accelerates intestinal aging and increases susceptibility to colitis by destabilizing cellular adhesion complexes. Population data from 182,213 individuals shows dietary magnesium intake of 334.7–420.0 mg/day significantly reduces risk of inflammatory bowel disease, irritable bowel syndrome, and related disorders.

Biological EDGE

Biohacking Starts With NO